Cargando…
Benzimidazoisoquinoline derivatives inhibit glioblastoma cell proliferation through down-regulating Raf/MEK/ERK and PI3K/AKT pathways
BACKGROUND: Recent studies showed that benzimidazoleisoquinolinone derivatives exhibit anticancer activity against human cancer cell lines. The aim of this study is to evaluate the anti-tumor effects and mechanisms of benzimidazoleisoquinolinones in isocitrate dehydrogenase-wildtype subtype of human...
Autores principales: | Zhang, Ya-Jun, Xu, Zhi-Gang, Li, Shi-Qiang, He, Liu-Jun, Tang, Yan, Chen, Zhong-Zhu, Yang, Dong-Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022716/ https://www.ncbi.nlm.nih.gov/pubmed/29988358 http://dx.doi.org/10.1186/s12935-018-0588-x |
Ejemplares similares
-
Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways in glioma cells
por: Du, Wei, et al.
Publicado: (2021) -
Targeting the PI3K/AKT/mTOR and RAF/MEK/ERK pathways for cancer therapy
por: Li, Qingfang, et al.
Publicado: (2022) -
MiR-155-5p suppresses SOX1 to promote proliferation of cholangiocarcinoma via RAF/MEK/ERK pathway
por: Wang, Da, et al.
Publicado: (2021) -
RAS/RAF/MEK/ERK and PI3K/PTEN/AKT Signaling in Malignant Melanoma Progression and Therapy
por: Yajima, Ichiro, et al.
Publicado: (2012) -
Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs
por: Haas, Bodo, et al.
Publicado: (2018)